News

Canon Medical Systems USA Inc. Announces Expansion of Distributorship with the Acquisition of NXC Imaging

Tustin, California, (GLOBE NEWSWIRE) — Canon Medical Systems USA Inc., a commercial subsidiary of Canon Medical Systems Corporation and a global leader in innovative diagnostic imaging technology, today announces it has signed a definitive agreement to acquire NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota. Founded in 1964, NXC Imaging’s distributorship area spans the U.S. Upper Midwest. The acquisition is expected to close in the third quarter of the 2022 calendar year.

The addition of NXC Imaging to Canon Medical Systems USA will strengthen its sales and service channels across the Upper Midwest in Canon’s diagnostic imaging portfolio that includes modalities of Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance (MR), X-ray (XR), Vascular Imaging (VL) and Ultrasound (UL). Canon Medical plans to continue building its substantial sales and service organization, offering innovative solutions and unique business models tailored to each client’s specific needs.

“We have partnered with NXC Imaging for over 33 years,” said Yuji Hamada, CEO and President of Canon Medical Systems USA Inc. “Our successful partnership has thrived due to Canon’s innovative technology and trusting collaboration with NXC’s entrepreneurial company culture. The results of our partnership have demonstrated strong results over the past 15 years in the Upper Midwest region.”

“Our company’s foundation was built on our long-term customer relationships, trust, and loyalty in our territories. As a result, we have provided exceptional technology solutions and best-in-class support. We are proud of the legacy we’ve created and know that as a part of Canon Medical, we will continue to provide the Upper Midwest region with the same “Never Ordinary” customer service we are known for,” stated Bruce Zeilinger, President, and CEO of NXC Imaging.

Read more here.

Recent News

06/12/2024

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has signed a research agreement with The School of Pharmacy at University College Cork, Ireland. The scope of the agreement encompasses the development of novel topical formulations of Rapamycin (sirolimus) as potential

06/11/2024

KeViRx, Inc. Awarded $1.99 Million

KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced today the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program. This grant funding will allow KeViRx to advance its first-in-class small molecule platform technology, KVX-053, toward IND for pulmonary microvascular leakage and inflammation during acute lung injury

05/31/2024

Virginia Catalyst Announces Round 17 of Grant Funding

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 16 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The mission of the Catalyst